Mineralys Therapeutics Stock (NASDAQ: MLYS) stock price, news, charts, stock research, profile.
Open | $13.25 |
Close | - |
Volume / Avg. | 38.78K / 194.22K |
Day Range | 13.11 - 13.35 |
52 Wk Range | 5.85 - 16.91 |
Market Cap | $662.81M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 54 |
Short Interest | 3.38% |
Days to Cover | 2.57 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Mineralys Therapeutics (NASDAQ:MLYS) through any online brokerage.
Other companies in Mineralys Therapeutics’s space includes: KalVista Pharma (NASDAQ:KALV), 4D Molecular Therapeutics (NASDAQ:FDMT), Celcuity (NASDAQ:CELC), Larimar Therapeutics (NASDAQ:LRMR) and Replimune Group (NASDAQ:REPL).
There is no analysis for Mineralys Therapeutics.
Mineralys Therapeutics has a consensus price target of $34.29.
The stock price for Mineralys Therapeutics (NASDAQ: MLYS) is $13.35 last updated Today at July 22, 2024 at 2:29 PM EDT.
There are no upcoming dividends for Mineralys Therapeutics.
Mineralys Therapeutics’s Q2 earnings are confirmed for Monday, August 5, 2024.
There is no upcoming split for Mineralys Therapeutics.
Mineralys Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.